ScreenerHero

SANN Santhera Pharmaceuticals Holding AG

SWX · CH · Healthcare · Biotechnology · santhera.com
15.48CHF+2.38%Mkt Cap: 270.65M $P/E: —

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Euro…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap270.65M USD
Enterprise Value247.08M USD
Revenue (TTM)115.84M USD
Gross Profit17.32M USD
Net Income (TTM)-56.19M USD
Revenue/Share7.35 CHF
Last Price15.48 CHF
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees93
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0027148649
Valuation
P/E (Trailing)—
P/E (Forward)88.94
PEG—
EV/EBITDA-59.52
EV/Revenue2.13
P/S2.28
P/B-17.14
EPS (TTM)-2.24
EPS (Forward)0.17
52W Range
9.38064% of range18.84
52W High18.84 CHF
52W Low9.380 CHF
Profitability
Gross Margin19.66%
Oper. Margin-13.58%
EBITDA Margin-3.58%
Profit Margin-63.79%
ROE416.69%
ROA-33.25%
Growth
Revenue Growth101.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.68M USD
CapEx (TTM)59.35K USD
FCF Margin-22.94%
FCF Yield-9.82%
Net Debt-563.80K USD
Net Debt/EBITDA0.14
Balance Sheet
Debt/Equity-4.14
Current Ratio1.73
Quick Ratio1.10
Book Value/Sh-0.88 CHF
Cash/Share2.91 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 CHF
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 8, 2022
Splits
Last Split1:10
Split DateJul 3, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.50 CHF
Upside (mean)+77.6%
Target Range25.00 CHF – 30.00 CHF
25.00+77.6% to mean30.00
# Analysts2
Ownership
Shares Out.15.32M
Float12.09M
Insiders11.15%
Institutions14.21%
Technical
SMA 5015.55 (-0.5%)
SMA 20015.40 (+0.5%)
Beta—
S&P 52W Chg14.58%
Avg Vol (30d)68.11K
Avg Vol (10d)69.94K
Technical Indicators
RSI (14)44.9
MACD-0.1396
MACD Signal-0.0751
MACD Hist.-0.0646
BB Upper16.60 CHF
BB Middle15.61 CHF
BB Lower14.63 CHF
BB Width12.66%
ATR (14)0.6048 CHF
Vol Ratio (20d)1.18x